Companies/Amneal Pharmaceuticals, Inc.

Company profile

Amneal Pharmaceuticals, Inc.

NASDAQ: AMRX · Healthcare · Drug Manufacturers - Specialty & Generic

PublicHQ Bridgewater, NJCIK 0001723128Reports USD

#86 of 1,394 Healthcare companies by revenue54th-percentile growth

EA Score

75B+

FH 86DQ 62GM 69SS 75

v0.1 · 65/100 weight · provisional

↑ balance-sheet leverage, growth stability · ↓ listing tenure, disclosure history

Methodology →

Revenue TTM

$3.0B

Rev growth YoY (TTM)

+7.6%

Net income (FY)

$72.1M

Employees

8,300

Market cap

$5.5B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$3.0B$3.0B2025

Net income$72.1M$72.1M2025

Operating income$394.1M$394.1M2025

Total assets$3.7B$3.7B2025

Liabilities$0$02017

Equity-$70.8M-$70.8M2025

Revenue trend

FY2019 – FY2025 · USD

$378.3M

FY19

$1.6B

FY19

$2.0B

FY20

$2.1B

FY21

$2.2B

FY22

$2.4B

FY23

$2.8B

FY24

$3.0B

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Specialty100%

By geography

Specialty100%

The read

Amneal Pharmaceuticals, Inc. booked $3.0B in FY2025 revenue, growing 8.0% year over year — about the middle of the pack among Healthcare companies we track, at a 2.4% net margin.

Peers · Healthcare

Legend Biotech Corporation——Veradermics, Incorporated——BillionToOne, Inc.53D RadNet, Inc.73B

Key facts

CEOChirag K. Patel

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersBridgewater, NJ

ExchangeNASDAQ: AMRX

Employees8,300

IPO date2018-05-07

Latest filings

10-Q2026-05-07 8-K2026-05-07 8-K2026-05-07 8-K2026-04-22 DEF 14A2026-03-25 8-K2026-02-27 10-K2026-02-27 8-K2026-02-03

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.